<Any thoughts on where the stock is headed?>
I'd thought that it would not go below the
price paid in that private offering, $14 or
$15 I think. So, while I was happy to buy my
shares back in the 13-18 range (I'd sold in
the lower to mid $20s) I am surprised Tgen
shares have come this low. A bit of a shakeout
perhaps? MM's shaking daytraders for loose change?
I think the downside risk is small, upside is decent
--some good news for the market sneaks out of ASCO
(or AACR?) meeting, and maybe you go back to the
old highs in short order. I'd thought that there
were phase II Cystic Fibrosis trials that were
being enrolled this year, whole lung, not the sinus
--with phase I... "data from the trial will be presented
in a scientific forum in 2000."
Naturally one hopes that you do a private offering and
then reward your new investors with positive news flow.
I have no idea at all whether good news might be the
E1A for cancer, or CF gene therapy, or something that
comes out of the blue.
Short answer, biotech sector finds a base,
then up again for Tgen. Nasdaq is down ten percent,
so if that is considered a correction, things
sometimes race back awfully fast. Its all trading
and momentum in this market.
ASCO Annual Meeting May 20-23, 2000
asco.org
AACR Annual Meeting, April 1-5, 2000
aacr.org
Don't know for sure if E1A data is presented
at one of these, saw ASCO on the Yahoo thread,
maybe so. |
